Chemo plus targeted drug for liver-metastatic colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding an EGFR-targeting antibody to chemotherapy can help people with colorectal cancer that has spread to the liver. It's for those whose tumors have a normal RAS gene and who have not had treatment before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- Your daily activity level is mostly normal (able to care for yourself).
- You have colorectal cancer that has spread to the liver and cannot be removed with surgery.
- Your tumor has a normal RAS gene (wild-type).
- You have not received any previous treatment for metastatic disease.
- Your blood counts and liver/kidney function are within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new way to give the chemotherapy drug paclitaxel directly into the liver (through a tiny tube) along with standard systemic treatment for people whose colorectal cancer has spread only to the liver and cannot be surgically removed. The goal is to see if this targeted approach works better than standard treatment alone.
This trial tests whether adding cetuximab to standard chemotherapy can improve outcomes for people with colorectal cancer that has spread only to the liver. It aims to see if the combination works better when specific tumor markers (RAS/BRAF) are “wild type” and the liver disease can be removed.
This Phase 3 trial tests different ways to deliver chemotherapy for colon cancer that has spread only to the liver (with limited possible tiny lung spots). It looks at whether the treatment plan improves outcomes compared with another chemotherapy approach, using oxaliplatin and LV5FU2 (with or without irinotecan) plus an added targeted medicine.
This trial tests a new drug (RC148) combined with standard chemotherapy as a first treatment for colorectal cancer that has spread or cannot be removed. The goal is to see if this combination works better than chemotherapy alone.
This Phase 3 trial tests a treatment approach for colorectal cancer that cannot be removed with surgery at first but has spread only to the liver. It is intended for people whose tumor is RAS/BRAF “wild-type” and who are well enough to do daily activities, to see if the treatment can control the cancer better.
This trial tests whether adding two targeted drugs (serplulimab and bevacizumab) to standard chemotherapy before surgery can improve outcomes for people with colorectal cancer that has spread to the liver. It is for those whose cancer has certain genetic features and is considered resectable.
Hear when a new Liver Metastases of Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.